Somnogenic Cytokines and Models Concerning Their Effects on Sleep

JAMES M. KRUEGER, Ph.D., a FERENC OBAL, Jr., Ph.D., M.D.; b MARK OPP, Ph.D., a LINDA TOTH, Ph.D., D.V.M.; c LARS JOHANNSEN, Ph.D., a AND ALAN B. CADY, Ph.D. a

Department of Physiology and Biophysics, University of Tennessee, Memphis, Tennessee; b Department of Physiology, University Medical School of Szeged, Szeged, Hungary; c Department of Comparative Medicine, University of Tennessee, Memphis, Tennessee

Received June 8, 1989

INTRODUCTION

The concept that sleep is regulated in part by humoral mechanisms is supported by experimental demonstrations of somnogenic substances in tissue fluids (reviewed, [1–4]). These experiments began at the turn of the century with Legendre and Pieron [5] and Ishimori [6], who described the accumulation during prolonged wakefulness of substances in cerebrospinal fluid (CSF) that induce excess sleep when transferred to recipient animals. Although the chemical identity of these substances was never established, today over 30 putative sleep factors (SFs) have been identified (reviewed, [2]). Most of these putative SFs are hormones, immunomodulators, and/or substances involved in endocrine and/or immune regulation.

Abbreviations: ACTH: adrenocorticotropic hormone α-MSH: alpha-melanocyte-stimulating hormone CNS: central nervous system CRF: corticotropin-releasing factor CSF: cerebrospinal fluid DSIP: delta sleep-inducing peptide EEG: electroencephalogram GH: growth hormone GRF: growth hormone-releasing factor ICV: intracerebroventricular IFNa2: interferon alpha2 IL-1: interleukin1 IL-6: interleukin 6 MP: muramyl peptide NREMS: non-rapid-eye-movement sleep PG: prostaglandin PHI: peptide histidine-isoleucine poly I:C: polyriboinosinic:polyribocytidyllic acid REMS: rapid-eye-movement sleep TNF: tumor necrosis factor SF: sleep factor VIP: vasoactive intestinal peptide

Address reprint requests to: James M. Krueger, Ph.D., Dept. of Physiology and Biophysics, University of Tennessee, Memphis, 894 Union Avenue, Memphis, TN 38163

Copyright © 1990 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.
Until recently, it was postulated that a SF, herein defined as any substance found within the body that alters sleep, would have biological actions specific to sleep and would act on central nervous system (CNS) executive sleep centers, which were also assumed to be concerned primarily with sleep regulation. A single CNS center necessary for sleep has not, however, been demonstrated. Furthermore, all SFs identified to date have multiple biological activities. Thus, a revision of the original assumptions is necessary. This review describes a model that links the sleep effects of many putative SFs in a sleep activational system.

The sleep activational system presented is fundamentally a biochemical model and, like all models, is provisional; the cellular localization of many of the specific components that are germane to sleep regulation is not known. Nevertheless, it is assumed that specific components of the model ultimately interact with either glia and/or neurons at various levels of the CNS and that such interactions lead to altered sleep. We propose that such a system would be responsive to the many autonomic and environmental parameters that influence sleep, yet would retain the capacity to regulate sleep selectively.

Rapid-eye-movement sleep (REMS) and non-rapid-eye-movement sleep (NREMS) are the two major types of sleep, although subdivisions of each of these classes have been made. To identify these states of vigilance, the electroencephalogram (EEG) and other physiological measurements, e.g., electromyogram, brain temperature, and motor activity, are recorded. REMS and NREMS states exist in most mammals. Sleep in animals, however, is slightly different from that of humans. Thus, species often used in sleep research, such as rats, cats, and rabbits, have sleep episodes that are relatively short, typically lasting only for a few minutes. These bouts of sleep occur sporadically throughout the 24-hour day, alternating with episodes of wakefulness, although the percentage of any given hour spent in sleep is strongly influenced by circadian rhythms.

PROMOTION OF SLEEP BY CYTOKINES

Attempts to identify a sleep-promoting substance accumulating in CSF during sleep deprivation (Factor S) [7] resulted in the discovery of the somnogenic activity of muramyl peptides [8]. The sleep-promoting muramyl peptide isolated from rabbit brain and from human urine has biochemical characteristics similar to those of Factor S obtained from CSF [9].

Muramyl peptides are monomeric building blocks of bacterial peptidoglycans and are released during processing of bacterial cell walls by mammalian macrophages [10,11]. Muramyl peptides, however, are not the only sleep-promoting substances that can be obtained from microorganisms. Endotoxin and its lipid A moiety, components of the cell wall of gram-negative bacteria, also promote NREMS [12,13]. In addition, recent experiments show that a synthetic double-stranded RNA, polyriboinosinic:polyribocytidylic acid (poly I:C) [14], and RNA extracted from influenza-infected lungs are somnogenic [15].

Although the structure and nature of these sleep-promoting agents of microbial origin are widely different, they have an important common feature: all of them stimulate a set of systemic host defense reactions collectively termed the acute-phase response. Manifestations of the acute-phase response include activation of the immune system, changes in hormone secretion and hepatic synthesis of plasma proteins, alterations in metabolism, and fever [16,17]. These changes are observed after infections or tissue damage. Increased lassitude or sleepiness is a common experience
during infectious diseases; these symptoms are regarded as part of the acute-phase response. Recent studies, in fact, have produced experimental evidence for enhancement of sleep during bacterial [18] and fungal [19] infections. It seems, therefore, that the somnogenic activities of muramyl peptides, endotoxin, or double-stranded RNA are associated with the capacity of these substances to stimulate the acute-phase response. This notion suggests that the mechanisms of the acute-phase response may provide clues for understanding sleep regulation.

The acute-phase response is under humoral regulation. The bioactive substances released from cells affected by infection, inflammation, or tissue damage reach a wide range of target organs, including the CNS. Classical examples of inflammatory mediators include histamine, prostaglandins, neuropeptides like substance P, hormones (cortisol, growth hormone [GH], and the like), and well-known neuronal transmitters like noradrenaline [16,17,20]. A special group of polypeptides, the cytokines, has, however, fundamental importance in the mediation of the acute-phase response. Muramyl peptides, endotoxin, and poly I:C are all well known for their ability to induce cytokine production. Although production of cytokines was formerly attributed to leukocytes, it has now been established that at least some cytokines can be released from a wide variety of cells [16] and that cytokines may act as general intercellular communication signals. The number of identified cytokines increases continuously, and interactions among cytokines are complicated and poorly understood. Some seem to act in parallel, whereas others may be involved in a cascade-like process or may inhibit each other [17,21]. The amount of individual cytokines released varies with the specific noxious agent [22], and this fact may be reflected by differences of the clinical symptoms of the acute-phase response. Nevertheless, one of the cytokines, interleukin 1 (IL-1), seems to have an essential role in the mediation of the acute-phase response. Administration of IL-1 elicits all of the studied clinical and laboratory changes characteristic of the acute-phase response, indicating that IL-1 either directly or through other cytokines can activate the complete machinery of this syndrome [16]. Indeed, IL-1 was even found to promote sleep [23].

Rabbits spend about 45–50 percent of daylight hours in NREMS and about 5–10 percent of the time in REMS (Fig. 1). When they are given IL-1, either intravenously or intracerebroventricularly (icv), the amount of time spent in NREMS increases to 60–70 percent or more [23]. The enhancement of NREMS occurs at the expense of both REMS and wakefulness (Fig. 1) [24]. These effects on sleep are observed within the first hour after administration of IL-1; in contrast, the increases in sleep after muramyl peptide (MP) administration appear only after a delay of one to two hours. IL-1-enhanced NREMS persists for three to 12 hours, depending on the dose. The animals continue to awaken spontaneously and maintain normal postures; thus, the excess NREMS seems to be physiologically normal. Another characteristic of NREMS induced by IL-1 is that it appears to be more intense than spontaneous sleep; EEG slow waves (0.5–4.0 Hz) of supranormal amplitudes are observed [23,24]. Similarly, the deep sleep that follows sleep deprivation is also characterized by EEG slow waves of very high amplitude [25]: these supranormal EEG slow waves are thought to be a measure of the intensity (or depth) of NREMS [26]. Thus, after either sleep deprivation or IL-1 treatment, enhanced NREMS seems to result from an exaggerated activation of physiological sleep mechanisms.

The term IL-1 refers to two polypeptides distinguished as IL-1α and IL-1β, which have some structural homologies, act on the same receptors, and have practically
identical biological actions when studied in various *in vitro* and *in vivo* tests [27]. The sleep effects of IL-1α and IL-1β are also very similar [28]. Increases in NREMS were also observed after administration of two other cytokines, tumor necrosis factor (TNF) [24] and interferon α2 (IFNα2) [29]. The somnogenic actions of these cytokines could be mediated through IL-1 (both TNF [30] and IFN can release IL-1, though this effect of IFNα2 is relatively weak [31]), or they could act independent of IL-1. TNF, for example, is known to share many of the biological actions of IL-1, although the cellular receptors for TNF and IL-1 (α or β) are different [32]. Similarly, the pyrogenic action of IFN is probably not mediated through IL-1 [33].

In considering the sleep-promoting effects of cytokines, particularly IL-1, our starting point was a pathological condition: the acute-phase response. When IL-1 is injected into an animal, increased sleep appears as part of the acute-phase response, accompanied by other symptoms like fever, elevated serum copper, and so on [16]. It is therefore important to determine whether the IL-1 mediation of sleep only functions under special conditions or also contributes to normal sleep regulation. Theoretical considerations and indirect evidence suggest that IL-1 can be involved in physiological sleep regulation [34].

It is reasonable to suppose that the various aspects of the acute-phase response are mediated at different sites and therefore can be separated. Thus, antipyretics inhibit IL-1-induced fever without attenuating the increases in NREMS [23]. Interleukin 6 (IL-6), a recently discovered cytokine, has been implicated in the mediation of certain IL-1 effects, such as synthesis of acute-phase proteins and fever [35]; icv administration of IL-6, in fact, elicits fever in rabbits. This response, however, is not coupled with
increased sleep (Fig. 2) [36]. It has been suggested, therefore, that endogenous IL-1 released in optimal concentrations at the proper effector site(s) may promote sleep without evoking the complete pattern of the acute-phase response [34].

Various cells can produce IL-1; however, macrophages are the primary source of blood-borne IL-1, which mediates various symptoms of the acute-phase response. Although plasma IL-1 activity reportedly peaks at the onset of NREMS in man [37], it is likely that IL-1 involved in physiological sleep regulation is of CNS origin. IL-1-like activity in the CSF varies with the sleep-wake cycle [38]. Receptors for IL-1 have been demonstrated in various structures in the CNS [39]. IL-1β mRNA is constitutively expressed in the brain [40]; glial cells are known to produce IL-1 [41]. Recently, IL-1-immunoreactive hypothalamic neurons were described [42]. These findings clearly indicate that IL-1 is not only a mediator of the acute-phase response but has physiological functions in the CNS.

**MULTIPLE SLEEP FACTORS: A SLEEP ACTIVATIONAL SYSTEM**

Based on various considerations, including their sleep-promoting effects, a great number of substances have been proposed as physiological SFs. Table 1 provides a summary of putative SFs. Note, however, that this list is probably far from complete. None of these substances are specific for sleep; most of them are well-known neuropeptides, transmitters, hormones, or immunomodulators. As a result of testing in various *in vitro* and *in vivo* systems, these substances have also been shown to interact; they might promote, stimulate, or inhibit the production or action of one another. If these
TABLE 1
Substances That Have Been Identified as Sleep Factors

| Category | Substance                                                                 | Reference(s) |
|----------|---------------------------------------------------------------------------|---------------|
| A        | Substances that enhance non-rapid-eye-movement sleep (NREMS):              |               |
|          | cholecystokinin (CCK)                                                     | [43,44]       |
|          | insulin                                                                   | [45,46]       |
|          | desacetyl-alpha-melanocyte-stimulating hormone (desacetyl-α-MSH)          | [47]          |
|          | interleukin 1 (IL-1)                                                      | [23,24]       |
|          | interferon α2 (IFNα2)                                                     | [29]          |
|          | tumor necrosis factor (TNF)                                               | [24]          |
|          | muramyl peptides (MPs)                                                    | [8,9]         |
|          | double-stranded RNA (dsRNA)                                               | [14,15]       |
|          | endotoxin/lipid A                                                        | [12,13]       |
| B        | Substances that enhance REMS:                                             |               |
|          | somatostatin                                                              | [46,48]       |
|          | growth hormone (GH)                                                      | [49–51]       |
|          | corticotropin-like intermediate lobe peptide (CLIP)                       | [47]          |
|          | vasoactive intestinal polypeptide (VIP)                                   | [52–56]       |
|          | peptide histidine-isoleucine (PHI)                                        | [56]          |
|          | prolactin (PRL)                                                          | [56,57]       |
|          | gamma-Br                                                                 | [58]          |
| C        | Substances that enhance both NREMS and REMS:                              |               |
|          | growth hormone-releasing factor (GRF)                                      | [59–62]       |
|          | delta sleep-inducing peptide (DSIP)                                       | [63–65]       |
|          | arginine vasotocin (AVT)                                                  | [66,67]       |
|          | prostaglandin D₂ (PGD₂)                                                   | [68,69]       |
|          | uridine                                                                   | [70]          |
|          | adenosine                                                                 | [71]          |
|          | serotonin (5HT)                                                          | [72]          |
| D        | Substances that inhibit sleep:                                            |               |
|          | α-MSH/adrenocorticotropic hormone (ACTH)                                   | [73,74]       |
|          | corticotropin-releasing factor (CRF)                                       | [59,75]       |
|          | endogenous opioids                                                        | [76]          |
|          | glucocorticoids                                                           | [77]          |
|          | thyrotropin-releasing hormone (TRH)                                        | [78]          |
|          | prostaglandin E₂ (PGE₂)                                                   | [69,79]       |
|          | neuropeptide Y                                                            | [80]          |

substances are in fact SFs, the interaction between them can be regarded as sleep regulation itself. We call the SFs linked through their interactions the sleep activational system. In this model, sleep is regulated through cascades of biochemical events; however, many of the pathways can also work in relative independence, and a wealth of feedback loops is involved. It is important to emphasize that at present we do not know the relative contribution of the individual substances to physiological sleep regulation. Furthermore, the interactions are derived from experiments in which sleep was not monitored; therefore, the role of these interactions in sleep regulation remains to be evaluated. With these considerations in mind, a part of the sleep activational system is depicted in Fig. 3; there is reasonable evidence to suppose that the substances and interactions shown are involved in sleep regulation [81,82].

Stimuli associated with duration of prior wakefulness and the circadian clock are generally assumed to be inputs for sleep regulation [26]. Although tissue fluid levels of
FIG. 3. Sleep activation system showing possible interaction between putative sleep factors and effects of those sleep factors on non-rapid-eye-movement sleep (NREMS) and rapid-eye-movement sleep (REMS). The usefulness of this model is that it provides concrete examples for testing experimentally. For example, one would predict that during bacterial infection, when the supply of MPs and/or LPS is increased, that NREMS should be enhanced because cytokine production is enhanced; this hypothesis, indeed, seems to be the case (see [18,19]). Another prediction, not yet tested, would be that if one lesioned the arcuate nucleus, thereby removing neurons containing CRF and alpha MSH, one would remove a negative feedback signal for IL-1: this procedure should result in a "right shifted" IL-1 dose-sleep response curve. dsRNA, double-stranded ribonucleic acid; LPS, lipopolysaccharide; MPs, muramyl peptides; 5HT, serotonin; TNF, tumor necrosis factor; IFN, interferon; IL-1, interleukin 1; PG, prostaglandin; CRF, corticotropin-releasing factor; POMC, proopiomelanocorticotropin; ACTH, adrenocorticotropic hormone; α-MSH, alpha melanocyte-stimulating hormone; CLIP, corticotropin-like intermediate lobe peptide; DSIP, delta sleep-inducing peptide; GRF, growth hormone-releasing factor; GH, growth hormone; SOM, somatostatin; CCK, cholecystokinin; PHI, peptide histidine isoleucine; VIP, vasoactive intestinal peptide; PRL, prolactin. Refer to Table 1 for original references concerning the sleep effects of these compounds. Left, lines; † indicates stimulation and − indicates inhibition. Arrows, right, indicate sleep effects: † indicates increases, † decreases, — no effect.
most of the substances depicted in Fig. 3 have circadian rhythms, the mechanisms responsible for these variations are not known. The effect of normal wakefulness on the turnover and release of SFs has not been studied, although the effects of sleep deprivation were tested on some of the substances. Sleep deprivation, however, is not a physiological condition; many functions might be affected by this stressor, and the specificity of the changes observed is difficult to determine. IL-1 activity in blood [83] and vasoactive intestinal peptide (VIP) immunoreactivity in the CSF [84] increase during sleep deprivation. GH secretion is inhibited during sleep deprivation, whereas recovery sleep is accompanied by greater GH release than normal [85–87]. This finding may indicate an activation of the hypothalamo-pituitary growth hormone-releasing factor (GRF)-GH axis. It is likely, however, that both wakefulness and the circadian clock act on many sites of the sleep activational system.

The body is continuously exposed to bacterial invasion from mucous surfaces, especially from the gut. Bacterial products may therefore have tonic stimulatory activity on the sleep activational system and may be of primary importance as inputs for sleep in infectious diseases [2]. As mentioned above, muramyl peptides from bacteria and endotoxin from gram-negative bacteria stimulate the release of cytokines. IL-1 and other cytokines, in turn, stimulate the prostaglandin (PG) metabolism [16,88]. Some PGs, e.g., PGD2, enhance sleep [68], while others, e.g., PGE2 [79], inhibit sleep; thus it is possible that IL-1 and/or other cytokines alter sleep through their effects on PGs. Furthermore, PGE2 inhibits IL-1 production and induces IL-1 receptor synthesis [89], thereby providing a somewhat complicated short-loop feedback system. The timing of these events in vivo remains unknown.

Association of NREMS and GH secretion has been documented in several species [90–92], suggesting a link between the two phenomena. It has recently been shown that icv administration of GRF, a hypothalamic peptide that stimulates pituitary GH secretion, also promotes sleep, especially NREMS [59–62]. GRF therefore is another probable input for sleep regulation, and the various stimuli which affect GRF release all possibly modulate sleep-wake activity. GRF may also be involved in IL-1 effects. IL-1 increases GH secretion through a hypothalamic effector(s) [93] that is (are) likely to be GRF. Although promotion of sleep and stimulation of GH secretion are regarded as two separate outputs of the hypothalamic GRF mechanism [62] (the actions on sleep are assumed to be mediated through basal forebrain projections of the GRF-containing neurons), the hormonal effects of GRF might contribute to sleep regulation. GH may provide negative feedback for NREMS [50], and there are indications that both GH [49–51] and somatostatin [48] (a hypothalamic factor inhibiting GH secretion; somatostatin release is stimulated by rising GH secretion and also by GRF) may promote REMS. VIP and peptide histidine-isoleucine (PHI) are CNS neuropeptides, and, among other functions, they act as hypothalamic releasing factors for pituitary prolactin secretion [94]. VIP, PHI, and prolactin all stimulate REMS [52–57]. Although IL-1 stimulates prolactin release via the hypothalamus [93], it inhibits prolactin secretion from the pituitary [95]. This latter mechanism might be involved in suppression of REMS after high doses of IL-1.

The function of the corticotropin-releasing factor (CRF)-adrenocorticotropic hormone (ACTH)-glucocorticoids hypothalamo-pituitary adrenal axis is largely under circadian control, independent of sleep-wake activity; however, sleep-related inhibition of this system can also be demonstrated for a short period after sleep onset [96,97]. CRF and ACTH-alpha-melanocyte-stimulating hormone (α-MSH), in turn, inhibit
Sleep [59,73–75], and CRF also inhibits GH secretion in rats through a hypothalamic mechanism [98]. The CRF-ACTH/α-MSH-glucocorticoid system is likely to act as a major feedback loop for IL-1 [99]. Hypothalamic CRF secretion is stimulated by IL-1 [100,101]. CRF attenuates IL-1-induced enhancement of NREMS (and fever) [75]; the effects may be mediated, at least in part, by stimulation of central opiomelanocortinergic neurons resulting in α-MSH release. Activation of pituitary ACTH secretion results in glucocorticoid release. Glucocorticoids inhibit IL-1 production and various IL-1 actions [99], though IL-1 receptor synthesis is enhanced [89].

Stability is a major characteristic of the proposed sleep activational system. This feature stems from the multiplicity of SFs, the wealth of sleep-promoting pathways which often act in parallel, providing alternative mechanisms, and from the numerous feedback loops. In such a system, manipulation of a single SF is not detrimental, though the extent of changes may vary with the importance of the factor involved. Therefore, removal of a SF or blockade of a part of the sleep activational system per se does not necessarily result in sleep loss (and certainly not in total insomnia), but rather in decreased sleep stability. Because of the reduced stability, however, the system becomes vulnerable; for example, exogenous or endogenous stimuli which are normally ineffective may produce impairment of sleep. For example, increased sensitivity to environmental stimuli is a frequent complaint of patients suffering from sleep disturbances.

Due to the stability of sleep regulation, manipulation of a single SF does not have a great influence on sleep. In fact, all the experimental manipulations that reliably produce increases in sleep, i.e., prolonged sleep deprivation, infectious disease, excessive exercise, and prolonged starvation, are not physiologic. In these cases, enhancement of sleep is likely to be mediated at various sites of action. After less aggressive sleep-promoting manipulations (slight acute increases in ambient temperature above thermoneutrality, food intake), the occurrence of sleep is a statistical rather than an obligate phenomenon, indicating that these stimuli affect the sleep activational system within normal circadian limits.

The effects of many of the putative SFs vary when tested under different experimental conditions (species, timing of the administration with respect to the circadian rhythm, habituation of the animals, and so on) [102]. The variation of the sleep-promoting actions of these substances might also result from the stability of the system. The effects of a sleep substance depend on the function, availability, and simultaneous actions of many other substances, and if all conditions are not met, the exogenous administration of a sleep factor might be ineffective. As discussed above, the circadian pacemaker provides input(s) to the sleep activational system and is therefore an important stabilizing factor. It has been recognized that some of the proposed SFs (uridine, PGD₂) are more effective when administered during the active cycle than in the rest cycle [102]. It is assumed that the exogenously applied substance competes with a high concentration of endogenously produced SFs for the same receptors in the rest period, whereas the majority of the receptors are free and available for the exogenous substance in the active cycle. Other SFs, like delta sleep-inducing factor (DSIP), seem to be more effective if there already exists a spontaneous sleep pressure, presumably because their actions require prior activation of some component of the sleep regulation system [103]. Since the CRF-ACTH-glucocorticoid axis is a negative feedback mechanism for the sleep-promoting and pyrogenic actions of cytokines, it is possible that the effects of exogenous IL-1 are attenuated when the endogenous
effects on neuronal glucose levels. It is assumed that if the combined value of the outputs from the three neuronal sets shown for an individual activity reaches 9, then an increase in that activity will occur. The output from any individual neuronal set is variable, although limited to the range shown, and depends on the degree of SF stimulation. Thus, the effect of SFs on sleep can be described as follows.

1 This model is formally set up as a threshold system; i.e., a certain level of activation must be reached before effects are observed. This method was used for ease of illustration. Similar models in which each neuronal set continuously provides some degree of activation/inhibition for each biological activity that it affects can also be constructed. The same conclusions are reached, although the quantitative description of the process is more lengthy and is unnecessary for this discussion.
1. Some neuronal sets contribute more (have a larger output value; e.g., Fig. 4, A, B > C) to sleep propensity than others; thus, some SFs are more important for normal sleep than others (e.g., SF-X has a greater potential for enhancing sleep than does SF-Z, Fig. 4).

2. If the output of two neuronal sets remains constant, maximal stimulation of a third neuronal set could permit the sleep threshold to be reached; that is, the exogenous administration of a SF may induce excess sleep.

3. In contrast, if sets B and C are at minimal output levels, maximal stimulation of set A alone will not initiate sleep.

4. Total sleep propensity would be reduced if one set were lesioned, although sleep would be possible if the remaining sets were driven to a greater degree. Thus, an inherent feature of this model is that no individual neuronal set causes sleep, but all individual sets contribute to overall sleep propensity.

Another concept depicted in Fig. 4 is that neuronal sets are involved in physiological functions other than sleep. To illustrate how responses specific to sleep could result from such a construction, we have included one additional physiological parameter in Fig. 4, body temperature, and, as in the case of sleep propensity, assigned hypothetical numerical values for the outputs from each neuronal set for that function. Again, we assume that a collective value of 9 (from all three sets) must be reached before an increase in body temperature occurs. If the concentrations of SFs W–Z are such that the output for A is 6, for B, 2, and for C, 1, then the combined outputs of sets A–C for sleep would be 9, thus increasing sleep propensity. In contrast, the combined outputs for body temperature would be 6 (because neural set A cannot contribute more than 3 to this activity); thus, body temperature would not be affected by this particular combination of SF concentrations; thereby a specific effect on sleep would be observed. In contrast, if we choose a scenario such that the concentrations of SFs permit an output of 3 for A, 1 for B, and 5 for C, then the combined outputs from the three sets for sleep would be 6, and that for body temperature 9. Thus, body temperature, but not sleep, would be enhanced under this particular combination of SF concentrations.

The data presented in Figs. 1 and 2 can be used as concrete examples to illustrate these ideas further. Thus, IL-1β (Fig. 1) may be considered sleep factor X (Fig. 4).
having the ability to interact strongly with both neuronal sets A and B to enhance NREMS propensity and also to interact with these sets to enhance body temperature. In contrast, IL-6 (Fig. 2) may be considered to be an additional factor (not illustrated and not a sleep factor in Fig. 4) that has the capacity to increase the output of neuronal set C for body temperature and, perhaps, other neuronal sets involved in temperature, but not sleep, regulation. It could not add significantly to NREMS propensity because it cannot interact with neuronal sets A and B and neuronal set C has only a limited capacity to alter NREMS.

It is possible that there are multiple sites in the brain hierarchically arranged to regulate sleep. At each level, something similar to Fig. 4 could be developed; however, the complexity may be different at each level of the hierarchy. At some levels, it is possible that no set would be specific for any physiological function, such as sleep, and all would be involved in regulation of two or more variables. We consider such a brain construction likely for any behavior as complex as sleep.

CONCLUSION

From the discussions presented here, it is clear that cytokines and many other substances alter sleep. We have presented a model of how the regulation of many SFs may be interrelated and another model illustrating how SFs may interact with various neuronal sets to produce specific sleep responses. Ten years ago, it would have been unrealistic to present such models because the roster of putative SFs was much smaller, and there was very little information concerning how SFs might affect each other; however, despite the great number of advances within the field of SFs, many questions remain unanswered. Major challenges that need to be addressed include: (1) How do SF concentrations change with sleep/wake cycles and under pathological conditions? (2) What is the timing of these changes? (3) Where do these changes take place? (4) Is one change linked directly to another?

ACKNOWLEDGEMENTS

This work was supported in part by the Office of Naval Research (N00014-85-K-0773), the U.S. Army Medical Research and Development Command (DAMD-17-86-C-6194), the National Institutes of Health (NS-25378 and NS-27250), and a University of Tennessee-Neuroscience Center of Excellence Postdoctoral Fellowship.

REFERENCES

1. Krueger JM, Obal F Jr, Toth L, Johannsen L, Cady AB, Opp M: Sleep factors: Models concerning their multiple interactions and specificity for sleep. In Endogenous Sleep Factors. Edited by S Inoué, JM Krueger. Wassenaar, Bouma Text, in press
2. Krueger JM, Obal F Jr, Johannsen L, Cady AB, Toth L: Endogenous slow-wave sleep substances. In Slow-Wave Sleep: Physiological, Pathophysiological and Functional Aspects. Edited by A Wauquier, C Dugovic, M Radulovacki. New York, Raven Press, 1986, pp 75–90
3. Koella WP: The organization and regulation of sleep. Experientia (Basel) 40:309–338, 1984
4. Bördy AA, Tobler I: The search for an endogenous "sleep substance." TIPS 1:356–358, 1980
5. Legendre R, Pieron H: Recherches sur le besoin de sommeil consecutif a une vielle prolongee. Z Allg Physiol 14:235–262, 1913
6. Ishimori K: True cause of sleep—a hypnogenic substance as evidenced in the brain of sleep-deprived animals. Tokyo Igakkai Zasshi 23:429–459, 1909
7. Pappenheimer JR, Miller TB, Goodrich CA: Sleep-promoting effects of cerebrospinal fluid from sleep-deprived goats. Proc Natl Acad Sci USA 58:513–517, 1967
5. Krueger JM, Pappenheimer JR, Karnovsky ML: Sleep-promoting effects of muramyl peptides. Proc Natl Acad Sci USA 79:6102–6106, 1982
6. Krueger JM, Pappenheimer JR, Karnovsky ML: The composition of sleep-promoting factor isolated from human urine. J Biol Chem 257:1664–1669, 1982
7. Vermeulen MW, Grey GR: Processing of Bacillus subtilis peptidoglycan by a mouse macrophage cell line. Infect Immun 46:476–483, 1984
8. Johansson L, Wecke J, Krueger JM: Macrophage processing of bacteria: CNS-active substances are produced. Soc Neurosci Abstr 13:261, 1987
9. Krueger JM, Kubillus S, Shoham S, Davenne D: Enhancement of slow-wave sleep by endotoxin and lipid A. Am J Physiol 251:R591–R597, 1986
10. Cady AB, Kotani S, Shibata M, Krueger JM: Somnogenic activities of synthetic lipid A. Infect Immun 57:396–403, 1989
11. Cady AB, Brown RK, Jones MN, Majde JA, Krueger JM: RNA from influenza-infected lungs increases slow-wave sleep and body temperature while decreasing REM sleep. FASEB J 3:A678, 1989
12. Dinarello CA: Interleukin-1. Rev Infect Dis 6:51–95, 1984
13. Gauldie J, Lamontagne L, Stadnyk A: Acute phase response in infectious disease. Surv Synth Path Res 4:126–151, 1985
14. Dinarello CA: Staphylococcus aureus alters sleep patterns in rabbits. Infect Immun 56:1785–1791, 1988
15. Dinarello CA: Measurement of immunoreactive interleukin-1β from human mononuclear cells: Optimization of recovery, inrasubject consistency, and comparison with interleukin-1α and tumor necrosis factor. Clin Immunol Immunopathol 49:424–438, 1988
16. Krueger JM, Walter J, Dinarello CA, Wolff SM, Chedid L: Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol 246:R994–R999, 1984
17. Shoham S, Davenne D, Cady AB, Dinarello CA, Krueger JM: Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. Am J Physiol 253:R142–R149, 1987
18. Pappenheimer JR, Koski G, Fencel V, Karnovsky ML, Krueger JM: Extraction of sleep-promoting Factor S from cerebrospinal fluid and from brains of sleep-deprived animals. J Neurophysiol 38:1299–1311, 1975
19. Borbély AA: A two process model of sleep regulation. Hum Neurobiol 1:195–204, 1982
20. Dinarello CA: Interleukin-1. FASEB J 2:108–115, 1988
21. Shibata M, Blatteis CM, Krueger JM, Obal F Jr, Opp M: Pyrogenic, inflammatory and somnogenic responses to cytokines: Differential modes of action. In Thermoregulation: Research and Clinical Application. Edited by P Lomax, E Schönbauern. Basel, Karger, 1989, pp 69–73
22. Krueger JM, Dinarello CA, Shoham S, Davenne D, Walter J, Kubillus S: Interferon alpha-2 enhances slow-wave sleep in rabbits. Int J Immunopharmac 9:23–30, 1987
23. Dinarello CA, Cannon LG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA Jr, O’Connor JV: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163:1433–1450, 1986
24. Haq AU, Maca RD: Role of IFN-γ and α in IL1 synthesis and secretion of in vitro differentiated human macrophages: A comparative study. Immunobiol 171:451–460, 1986
25. Dinarello CA: Interleukin-1: Amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (cachectin). Year in Immunology 2:68–89, 1986
26. Dinarello CA, Bernheim HA, Duff GW, Le HV, Nagabhushan TL, Hamilton NC, Coceani F: Mechanisms of fever induced by recombinant human interferon. J Clin Invest 74:906–913, 1984
27. Krueger JM, Toth LA, Cady AB, Johanssen L, Obal F Jr: Immunomodulation and sleep. In Sleep Peptides. Edited by S Inoué, D Schneider-Helmert. Tokyo, VNU Press, 1988, pp 95–129
35. Helle M, Brakenhoff JPJ, De Groot ER, Aarden LA: Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol 18: 957–959, 1988

36. Opp M, Obal F Jr, Cady AB, Johanssen L, Krueger JM: Interleukin 6 is pyrogenic but not somnogenic. Physiol Behav 45:1069–1072, 1989

37. Moldofsky H, Lue FA, Eisen J, Keystone E, Gorczynski RM: The relationship of interleukin-1 and immune functions to sleep in humans. Psychosom Med 48:309–318, 1986

38. Lue FA, Bail M, Gorczynski R, Moldofsky H: Sleep and interleukin-1-like activity in cat cerebrospinal fluid. Sleep Res 16:51, 1987

39. Farrar WL, Kilan PL, Ruff MR, Hill JM, Pert CB: Visualization and characterization of interleukin 1 receptors in brain. J Immunol 139:459–463, 1987

40. Farrar WL, Hill JM, Harel-Bellan A, Vinocour M: The immune logical brain. Immunol Rev 100:361–377, 1987

41. Fontana A, Kristensen F, Dubs R, Gersba D, Weber E: Production of prostaglandin E and an interleukin 1-like factor by cultured astrocytes and C6 glioma cells. J Immunol 129:2413–2419, 1982

42. Breder CD, Dinarello CA, Saper CB: Interleukin-1 immunoreactive innervation of human hypothalamus. Science 240:321–324, 1988

43. Mansbach RS, Lorenz DN: Cholecystokinin (CCK-8) elicits prandial sleep in rats. Physiol Behav 30:179–183, 1983

44. Kapas L, Obal F Jr, Alfoldi P, Rubicsek G, Penke B, Obal F: Effects of nocturnal cholecystokinin in rats: Simultaneous increase in sleep, increase in EEG slow wave activity, reduction of motor activity, suppression of eating, and decrease in brain temperature. Brain Res 438:155–164, 1988

45. Danguir J, Nicolaidis S: Chronic intracerebroventricular infusion of insulin causes selective increase of slow wave sleep in rats. Brain Res 306:97–103, 1984

46. Danguir J: Insulin and somatostatin as sleep-inducing factors. In Endogenous Sleep Factors. Edited by S Inoué, JM Krueger. Wassenaar, Bouma Text, in press

47. Chastrette N, Cespuglio R: Influence of proopiomelanocortin-derived peptides on the sleep-waking cycle of the rat. Neurosci Lett 62:365–370, 1985

48. Danguir J: Intracerebroventricular infusion of somatostatin selectively increases paradoxical sleep in rats. Brain Res 367:26–30, 1986

49. Drucker-Colin RR, Spanis CW, Hunyadi J, Sassin JF, McGaugh JL: Growth hormone effects on sleep and wakefulness in the rat. Neuroendocrinology 18:1–18, 1975

50. Mendelson WB, Slater S, Gold P, Gillin JC: The effect of growth hormone administration on human sleep: A dose-response study. Biol Psychiatry 15:613–618, 1980

51. Stern WC, Jalowiec E, Shabshelowitz H, Morgane P: Effects of growth hormone on sleep-waking patterns in cats. Horm Behav 6:189–196, 1975

52. Riou F, Cespuglio R, Jouvet M: Endogenous peptides and sleep in the rat. III. The hypnogenic properties of vasoactive intestinal polypeptide (VIP). Neuropeptides 2:255–264, 1982

53. Drucker-Colin R, Bernal-Pedraza J, Fernandez-Cancino F, Oksenberg A: Is vasoactive polypeptide (VIP) a sleep factor? Peptides 5:837–840, 1984

54. Obal F Jr, Sary G, Alfoldi P, Rubicsek G, Obal F: Vasoactive intestinal polypeptide promotes sleep without effects on brain temperature in rats at night. Neurosci Lett 64:236–240, 1986

55. Kruisbrink J, Miriman M, Van der Woude TP, Boer GJ: Effects of enhanced cerebrospinal fluid levels of vasopressin, vasoressin antagonist or vasoactive intestinal polypeptide on circadian sleep-wake rhythm in the rat. Brain Res 419:76–86, 1987

56. Obal F Jr, Opp M, Cady AB, Johanssen L, Krueger JM: Prolactin, vasoactive intestinal peptide, and peptide histidine ethionine elicit selective increases in REM sleep in rabbits. Brain Res 490:292–300, 1989

57. Jouvet M, Buda C, Cespuglio R, Chastrette N, Denoyer M, Sallanon M, Sastre JP: Hypnogenic effects of some hypothalamic-pituitary peptides. Clin Neuropharmacol 9(Supplement 4):465–467, 1986

58. Torii S, Mutsunori K, Inubushi S, Yanagisawa I: The REM sleep-inducing action of a naturally occurring organic bromine compound in the encephale isolé cat. Psychopharmacologia 29:65–75, 1973

59. Ehlers CL, Reed TK, Henriksen SJ: Effects of corticotropin-releasing factor and growth hormone-releasing factor on sleep and activity in rats. Neuroendocrinology 42:467–474, 1986

60. Obal F Jr: Effects of peptides (DSIP, DSIP analogues, VIP, GRF and CCK) on sleep in the rat. Clin Neuropharmacol 9(Supplement 4):459–461, 1986
61. Nistico G, De Sarro GB, Bagetta G, Müller EE: Behavioural and electrocortical spectrum power effects of growth hormone releasing factor in rats. Neuropharmacology 26:75–78, 1987
62. Obal F Jr, Alföldi P, Cady AB, Johannsen L, Sary G, Krueger JM: Growth hormone-releasing factor enhances sleep in rats and rabbits, Am J Physiol 255(24):R310–R316, 1988
63. Schoenenberger GA, Maier PF, Tobaler HJ, Wilson K, Monnier M: The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflügers Arch 376:119–129, 1978
64. Graf MV, Kastin AJ: Delta-sleep-inducing peptide (DSIP): A review. Neurosci Biobehav Rev 8:83–93, 1984
65. Graf MV, Kastin AJ: Delta-sleep-inducing peptide (DSIP): An update. Peptides 7:1165–1187, 1986
66. Pavel S, Psatta D, Goldstein R: Slow-wave sleep induced in cats by extremely small amounts of synthetic and pineal vasotocin injected into the third ventricle of the brain. Brain Res Bull 2:251–254, 1977
67. Pavel S, Goldstein R, Petrescu M, Popa M: REM sleep induction in prepubertal boys by vasotocin: Evidence for the involvement of serotonin containing neurons. Peptides 2:245–250, 1981
68. Ueno R, Honda K, Inoué S, Hayashi O: Prostaglandin D2, a cerebral sleep-inducing substance in rats. Proc Natl Acad Sci USA 80:1735–1737, 1983
69. Hayashi O: Sleep-wake regulation by PGD2 and E2. J. Biol Chem 263:14593–14596, 1988
70. Inoué S, Honda K, Komoda Y, Uchizono K, Ueno R, Hayashi O: Differential sleep-promoting effects of five sleep substances nocturnally infused in unrestrained rats. Proc Natl Acad Sci USA 81:6240–6244, 1984
71. Radulovacki M, Virus RM, Djuricic-Nedelson M, Green RD: Adenosine analogs and sleep in rats. J Pharmacol Exp Ther 228:268–274, 1984
72. Jouvet M: Hypnogenic indolamine-dependent factors and paradoxical sleep rebound. In Sleep '82. Edited by WP Koella. Basel, Karger, 1983, pp 2–18
73. Concu A, Ferrari W, Gessa GL, Mereu GP, Tagliamonte A: EEG changes induced by the intraventricular injection of ACTH in cats. In Sleep 1974. Edited by P Levin, WP Koella. Basel, Karger, 1975, pp 321–325
74. Opp MR, Obal F Jr, Krueger JM: Effects of α-MSH on sleep, behavior, and brain temperature: Interactions with IL-1. Am J Physiol 255:R914–R922, 1988
75. Opp M, Obal F Jr, Krueger M: CRF attenuates interleukin-1 induced sleep and fever in rabbits. Am J Physiol 257:R528–R535, 1989
76. Dzoljic MR, Ukpomnwam OE, Ruprecht J, Haffmans J: Role of the enkephalinergic system in sleep studied by an enkephalinase inhibitor. In Sleep: Neurotransmitters and Neurmodulators. Edited by A Wauquier, JM Monti, JM Gaillard, MR Radulovacki. New York, Raven Press, 1985, pp 251–263
77. Gillin JC, Jacobs LS, Fram DH, Snyder F: Acute effect of a glucocorticoid on normal human sleep. Nature 237:398–399, 1972
78. Takahashi Y, Usui S, Ebihara S, Honda Y: Effects of continuous infusions of TRH and GIF on circadian rhythm parameters of sleep, ambulation, eating, and drinking in rats. In Endogenous Sleep Substances and Sleep Regulation. Edited by S Inoué, AA Borbely. Tokyo, Japan Scientific Societies Press/ Utrecht, VNU Science Press BV, 1985, pp 101–112
79. Matsumura H, Goh Y, Ueno R, Sakai T, Hayashi O: Awakening effect of PGE2 microinjected into the preoptic area of rats. Brain Res 444:265–272, 1988
80. Zini I, Pich EM, Fuxe K, Lenzi PL, Agnati LF, Harfstrand A, Mutt V, Tatemoto K, Moscara M: Actions of centrally administered neuropeptide Y on EEG activity in different rat strains and in different phases of their circadian cycle. Acta Physiol Scand 122:71–77, 1984
81. Krueger JM, Obal F Jr, Opp M, Cady AB, Johannsen L, Toth LA, Majde J: Putative sleep neuromodulators. In Sleep and Biological Rhythms. Edited by J Montplaisir. New York, Oxford University Press, in press
82. Obal F Jr, Opp M, Sary G, Krueger JM: Endocrine mechanisms in sleep regulation. In Endogenous Sleep Factors. Edited by S Inoué, JM Krueger. Wassenaar, Bouma Text, in press
83. Moldofsky H, Lue FA, Davidson JR, Gorczynski R: The effect of 40 hours of wakefulness on immune functions in humans. II. Interleukins-1 and -2-like activities. Sleep Res 17:34, 1988
84. Drucker-Colin R, Prospero-Garcia O, Arankowsky-Sandoval G, Perez-Monfort R: Gastropancreatic peptides and sensory stimuli as REM sleep factors. In Sleep Peptides: Basic and Clinical Approaches.
107. Moldofsky H, Davidson JR, Lue FA: Sleep-related patterns of plasma growth hormone and cortisol following 40 hours of wakefulness. Sleep Res 17:69, 1988

88. Dinarello CA, Bernheim HA: Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro. J Neurochem 37: 702–708, 1981

89. Akahoshi T, Oppenheim J, Matsushima K: Induction of IL1 receptor expression on fibrocytes by glucocorticoid hormone, prostaglandins and interleukin-1 (IL1). J Leukocyte Biol 42:579, 1987

90. Sassin JF: Sleep-related hormones. In Neurobiology of Sleep and Memory. Edited by RR Drucker-Colin, J McEachron. New York, Academic Press, 1977, pp 361–372

91. Takahashi Y: Growth hormone secretion related to sleep and waking rhythm. In The Functions of Sleep. Edited by RR Drucker-Colin, M. Shkurovich, MB Sterman. New York, Academic Press, 1979, pp 113–145

92. Oswald I: The function of sleep in restoring the tissues. In Sleep '86. Edited by WP Koella, F Obal, H Schulz, P Visser. Stuttgart, Fischer Verlag, 1988, pp 23–28

93. Rettori V, Jurcovicova J, McCann SM: Central action of interleukin-1 in alerting the release of TSH, growth hormone and prolactin in the male rat. J Neurosci Res 18:179–183, 1987

94. Kaji H, Chihara K, Abe H, Kita T, Kashiyo Y, Okimura Y, Fujita T: Effect of passive immunization with antisera to vasoactive intestinal polypeptide and peptide histidine isoleucine amide on 5-hydroxy-L-tryptophan-induced prolactin release in rats. Endocrinology 117:1914–1919, 1985

95. Bernton EW, Beach JE, Holaday JW, Smallridge RC, Fein HG: Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 238:519–521, 1987

96. Weitzman ED, Nogaire C, Perlow M, Fukushima D, Sassin J, McGregor P, Gallagher TF, Hellman L: Effects of a prolonged 3-hour sleep-wake cycle on sleep stages, plasma cortisol, growth hormone and body temperature in man. J Clin Endocrinol Metab 38:1018–1030, 1974

97. Mitsugi N, Kimura F: Simultaneous determination of blood levels of corticosterone and growth hormone in the male rat: Relation to sleep-wakefulness cycle. Neuroendocrinology 41:125–130, 1985

98. McCann M, Ono N, Khorram O, Kentroti S, Aguil C: The role of brain peptides in neuroimmunomodulation. Ann NY Acad Sci 496:173–181, 1987

99. Lumpkin MD: The regulation of ACTH secretion by IL1. Science 238:452–454, 1987

100. Sapolsky R, Rivier C, Yamamoto G, Plootsky P, Vale W: Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 238:522–524, 1987

101. Berkenbosch F, van Oers J, Del Ray A, Tilders F, Besedovsky H: Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 238:524–526, 1987

102. Inoué S: Biology of Sleep Substances. Boca Raton, CRC Press, 1989

103. Obal F Jr, Kovály ZM, Kalikhevich VN, Török A, Alföldi P, Sary G, Hajos M, Penke B: Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep. Pharmacol Biochem Behav 24:889–894, 1986

104. Shoham S, Krueger JM: Muramyl dipeptide-induced sleep and fever; effects of ambient temperature and time of injection. Am J Physiol 255:R157–R165, 1988

105. Obal F Jr, Rubicsek G, Alföldi P, Sary G, Obal F: Changes in the brain and core temperatures in relation to the various arousal states in rats in the light and dark periods of the day. Pfügers Arch 404:73–79, 1985

106. Walter J, Davenne D, Shoham S, Dinarello CA, Krueger JM: Brain temperature changes coupled to sleep states persist during interleukin-1 enhanced sleep. Am J Physiol 250: R96–R103, 1986

107. McGinty DJ: Physiological equilibrium and the control of sleep states. In Brain Mechanisms of Sleep. Edited by DJ McGinty, R Drucker-Colin, A Morrison, PL Parmeggiani. New York, Raven Press, 1985, pp 361–384